Angle posts positive prostate cancer treatment tests update

Researchers from Barts Cancer Institute, which is carrying out the tests, were able to successfully harvest circulating tumor cells from all the 52 assessed patients.

The group said the research suggests the cells harvested by its Parsotix system are "clinically relevant", which mean they could be used to provide a repeatable, non-invasive liquid biopsy for prostate cancer patients.

Angle's founder and chief executive Andrew Newland said the findings were encouraging, while Yong-Jie Lu from the Barts Cancer Institute hoped that "this may help guide effective treatment for prostate cancer patients in the future".

Prostate cancer is the second most common cancer in men ahd the fourth most common overall.

Shares in Angle were up 2.47% to 95.3p on Thursday at 11:32.